Description

Briakinumab is a high-purity, fully human monoclonal antibody targeting the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23). This compound is a critical research and development tool for investigating the pathophysiology and therapeutic modulation of immune-mediated inflammatory diseases. Briakinumab CAS NO 339308-60-0 is primarily utilized by pharmaceutical R&D teams, biotechnology companies, and academic research institutions focused on immunology and autoimmune disorders.

Application

• Biopharmaceutical Research & Development: A key reference standard and active pharmaceutical ingredient (API) in pre-clinical and clinical-stage drug development programs targeting IL-12/IL-23 pathways.
• Immunology Mechanism Studies: Used in in vitro and in vivo models to elucidate the role of IL-12 and IL-23 in autoimmune and chronic inflammatory conditions.
• Therapeutic Antibody Benchmarking: Serves as a critical comparator for the development and characterization of next-generation biologic therapies for psoriasis, psoriatic arthritis, and Crohn's disease.
• Diagnostic Reagent Development: Employed in the development of immunoassays and diagnostic kits to detect and quantify specific cytokines or related biomarkers in biological samples.
• Cell Signaling & Pathway Analysis: A vital tool for studying T-helper cell (Th1 and Th17) differentiation and function in research laboratories.

Basic Information

Product Name	Briakinumab
CAS No.	339308-60-0
Molecular Formula	C6420H9916N1720O2016S46
Molecular Weight	Approx. 144 kDa
Synonyms	ABT-874; Anti-IL-12/IL-23 p40 Monoclonal Antibody; IL-12/IL-23 Inhibitor; Human IgG1κ Monoclonal Antibody (anti-IL12/23p40); Monoclonal Antibody to Interleukin 12, p40 Subunit; Monoclonal Antibody to Interleukin 23, p40 Subunit
EINECS	Contact for details

Quality Control

Our Briakinumab is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical characterization to ensure identity, purity, potency, and consistency. We provide full traceability and Certificates of Analysis (COA) detailing results from orthogonal methods including HPLC, SDS-PAGE, and bioactivity assays. Production adheres to cGMP guidelines where applicable, supporting its use in regulated research and development.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store lyophilized material at -20°C or below. Reconstituted solutions should be aliquoted and stored at -80°C to avoid repeated freeze-thaw cycles. This product is hygroscopic (moisture-sensitive).

Specification

Item	Specification
Appearance	White to off-white lyophilized powder or clear solution
Identification (HPLC/MS)	Conforms to reference standard
Purity (SDS-PAGE, reduced & non-reduced)	> 95%
Purity (SEC-HPLC)	> 98% Monomer
Protein Content (UV Absorbance)	> 1.0 mg/mL (for solutions)
Endotoxin Level (LAL)	< 1.0 EU/mg
Biological Activity (Cell-based assay)	IC50 as per COA
Sterility (Membrane Filtration)	Sterile

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.